This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abella, J. V.
Right arrow Articles by Park, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abella, J. V.
Right arrow Articles by Park, M.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, November 2005, p. 9632-9645, Vol. 25, No. 21
0270-7306/05/$08.00+0     doi:10.1128/MCB.25.21.9632-9645.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Met/Hepatocyte Growth Factor Receptor Ubiquitination Suppresses Transformation and Is Required for Hrs Phosphorylation

Jasmine V. Abella,1,{dagger} Pascal Peschard,1,{dagger} Monica A. Naujokas,2 Tong Lin,2 Caroline Saucier,2 Sylvie Urbé,4 and Morag Park1,2,3*

Departments of Biochemistry,1 Medicine,2 Oncology, McGill University, Montréal, Québec, Canada,3 Physiological Laboratory, University of Liverpool, Liverpool, United Kingdom4

Received 13 May 2005/ Returned for modification 21 June 2005/ Accepted 9 August 2005

The Met receptor tyrosine kinase (RTK) regulates epithelial remodeling, dispersal, and invasion and is deregulated in many human cancers. It is now accepted that impaired down-regulation, as well as sustained activation, of RTKs could contribute to their deregulation. Down-regulation of the Met receptor involves ligand-induced internalization, ubiquitination by Cbl ubiquitin ligases, and lysosomal degradation. Here we report that a ubiquitination-deficient Met receptor mutant (Y1003F) is tumorigenic in vivo. The Met Y1003F mutant is internalized, and undergoes endosomal trafficking with kinetics similar to the wild-type Met receptor, yet is inefficiently targeted for degradation. This results in sustained activation of Met Y1003F and downstream signals involving the Ras-mitogen-activated protein kinase pathway, cell transformation, and tumorigenesis. Although Met Y1003F undergoes endosomal trafficking and localizes with the cargo-sorting protein Hrs, it is unable to induce phosphorylation of Hrs. Fusion of monoubiquitin to Met Y1003F is sufficient to decrease Met receptor stability and prevent sustained MEK1/2 activation. In addition, this rescues Hrs tyrosine phosphorylation and decreases transformation in a focus-forming assay. These results demonstrate that Cbl-dependent ubiquitination is dispensable for Met internalization but is critical to target the Met receptor to components of the lysosomal sorting machinery and to suppress its inherent transforming activity.

* Corresponding author. Mailing address: Molecular Oncology Group H5.21, McGill University Health Centre, 687 Pine Ave. West, Montréal, Québec, Canada H3A 1A1. Phone: (514) 934-1934, ext. 35845. Fax: (514) 843-1478. E-mail: morag.park{at}mcgill.ca.

{dagger} These authors contributed equally to this work.

Molecular and Cellular Biology, November 2005, p. 9632-9645, Vol. 25, No. 21
0022-538X/05/$08.00+0     doi:10.1128/MCB.25.21.9632-9645.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • St-Germain, J. R., Taylor, P., Tong, J., Jin, L. L., Nikolic, A., Stewart, I. I., Ewing, R. M., Dharsee, M., Li, Z., Trudel, S., Moran, M. F. (2009). Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc. Natl. Acad. Sci. USA 106: 20127-20132 [Abstract] [Full Text]  
  • Ponzo, M. G., Lesurf, R., Petkiewicz, S., O'Malley, F. P., Pinnaduwage, D., Andrulis, I. L., Bull, S. B., Chughtai, N., Zuo, D., Souleimanova, M., Germain, D., Omeroglu, A., Cardiff, R. D., Hallett, M., Park, M. (2009). Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc. Natl. Acad. Sci. USA 106: 12903-12908 [Abstract] [Full Text]  
  • Abella, J. V., Park, M. (2009). Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am. J. Physiol. Endocrinol. Metab. 296: E973-E984 [Abstract] [Full Text]  
  • Parachoniak, C. A., Park, M. (2009). Distinct Recruitment of Eps15 via Its Coiled-coil Domain Is Required For Efficient Down-regulation of the Met Receptor Tyrosine Kinase. J. Biol. Chem. 284: 8382-8394 [Abstract] [Full Text]  
  • Gao, X., Lorinczi, M., Hill, K. S., Brooks, N. C., Dokainish, H., Ireton, K., Elferink, L. A. (2009). Met Receptor Tyrosine Kinase Degradation Is Altered in Response to the Leucine-rich Repeat of the Listeria Invasion Protein Internalin B. J. Biol. Chem. 284: 774-783 [Abstract] [Full Text]  
  • Coleman, D. T., Bigelow, R., Cardelli, J. A. (2009). Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Molecular Cancer Therapeutics 8: 214-224 [Abstract] [Full Text]  
  • Sangwan, V., Paliouras, G. N., Abella, J. V., Dube, N., Monast, A., Tremblay, M. L., Park, M. (2008). Regulation of the Met Receptor-tyrosine Kinase by the Protein-tyrosine Phosphatase 1B and T-cell Phosphatase. J. Biol. Chem. 283: 34374-34383 [Abstract] [Full Text]  
  • Tanaka, Y., Tanaka, N., Saeki, Y., Tanaka, K., Murakami, M., Hirano, T., Ishii, N., Sugamura, K. (2008). c-Cbl-Dependent Monoubiquitination and Lysosomal Degradation of gp130. Mol. Cell. Biol. 28: 4805-4818 [Abstract] [Full Text]  
  • Padron, D., Sato, M., Shay, J. W., Gazdar, A. F., Minna, J. D., Roth, M. G. (2007). Epidermal Growth Factor Receptors with Tyrosine Kinase Domain Mutations Exhibit Reduced Cbl Association, Poor Ubiquitylation, and Down-regulation but Are Efficiently Internalized. Cancer Res. 67: 7695-7702 [Abstract] [Full Text]  
  • Li, N., Lorinczi, M., Ireton, K., Elferink, L. A. (2007). Specific Grb2-mediated Interactions Regulate Clathrin-dependent Endocytosis of the cMet-tyrosine Kinase. J. Biol. Chem. 282: 16764-16775 [Abstract] [Full Text]  
  • Toyoshima, M., Tanaka, N., Aoki, J., Tanaka, Y., Murata, K., Kyuuma, M., Kobayashi, H., Ishii, N., Yaegashi, N., Sugamura, K. (2007). Inhibition of Tumor Growth and Metastasis by Depletion of Vesicular Sorting Protein Hrs: Its Regulatory Role on E-Cadherin and {beta}-Catenin. Cancer Res. 67: 5162-5171 [Abstract] [Full Text]  
  • Shattuck, D. L., Miller, J. K., Laederich, M., Funes, M., Petersen, H., Carraway, K. L. III, Sweeney, C. (2007). LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy. Mol. Cell. Biol. 27: 1934-1946 [Abstract] [Full Text]  
  • Stern, K. A., Visser Smit, G. D., Place, T. L., Winistorfer, S., Piper, R. C., Lill, N. L. (2007). Epidermal Growth Factor Receptor Fate Is Controlled by Hrs Tyrosine Phosphorylation Sites That Regulate Hrs Degradation. Mol. Cell. Biol. 27: 888-898 [Abstract] [Full Text]  
  • Hoffmann, K. M., Tapia, J. A., Berna, M. J., Thill, M., Braunschweig, T., Mantey, S. A., Moody, T. W., Jensen, R. T. (2006). Gastrointestinal Hormones Cause Rapid c-Met Receptor Down-regulation by a Novel Mechanism Involving Clathrin-mediated Endocytosis and a Lysosome-dependent Mechanism. J. Biol. Chem. 281: 37705-37719 [Abstract] [Full Text]  
  • Yamamoto, N., Mammadova, G., Song, R. X.-D., Fukami, Y., Sato, K.-i. (2006). Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J. Cell Sci. 119: 4623-4633 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»